Trial Profile
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent/ CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Bevacizumab; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel; Paclitaxel
- Indications Adenocarcinoma; Clear cell sarcoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 19 Oct 2021 Status changed from active, no longer recruiting to completed.
- 17 Feb 2021 Results of a post-hoc analysis published in the Gynecologic Oncology
- 07 Nov 2019 Results to determine the maximum tolerated dose of veliparib published in the Gynecologic Oncology